Host-directed therapies for tuberculosis : quantitative systems pharmacology approaches
Copyright © 2021 Elsevier Ltd. All rights reserved..
Host-directed therapies (HDTs) that modulate host-pathogen interactions offer an innovative strategy to combat Mycobacterium tuberculosis (Mtb) infections. When combined with tuberculosis (TB) antibiotics, HDTs could contribute to improving treatment outcomes, reducing treatment duration, and preventing resistance development. Translation of the interplay of host-pathogen interactions leveraged by HDTs towards therapeutic outcomes in patients is challenging. Quantitative understanding of the multifaceted nature of the host-pathogen interactions is vital to rationally design HDT strategies. Here, we (i) provide an overview of key Mtb host-pathogen interactions as basis for HDT strategies; and (ii) discuss the components and utility of quantitative systems pharmacology (QSP) models to inform HDT strategies. QSP models can be used to identify and optimize treatment targets, to facilitate preclinical to human translation, and to design combination treatment strategies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Trends in pharmacological sciences - 43(2022), 4 vom: 15. Apr., Seite 293-304 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mehta, Krina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 08.04.2022 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tips.2021.11.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334522943 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334522943 | ||
| 003 | DE-627 | ||
| 005 | 20231225223858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tips.2021.11.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334522943 | ||
| 035 | |a (NLM)34916092 | ||
| 035 | |a (PII)S0165-6147(21)00233-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mehta, Krina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Host-directed therapies for tuberculosis |b quantitative systems pharmacology approaches |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2022 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Host-directed therapies (HDTs) that modulate host-pathogen interactions offer an innovative strategy to combat Mycobacterium tuberculosis (Mtb) infections. When combined with tuberculosis (TB) antibiotics, HDTs could contribute to improving treatment outcomes, reducing treatment duration, and preventing resistance development. Translation of the interplay of host-pathogen interactions leveraged by HDTs towards therapeutic outcomes in patients is challenging. Quantitative understanding of the multifaceted nature of the host-pathogen interactions is vital to rationally design HDT strategies. Here, we (i) provide an overview of key Mtb host-pathogen interactions as basis for HDT strategies; and (ii) discuss the components and utility of quantitative systems pharmacology (QSP) models to inform HDT strategies. QSP models can be used to identify and optimize treatment targets, to facilitate preclinical to human translation, and to design combination treatment strategies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Mycobacterium tuberculosis | |
| 650 | 4 | |a host-directed therapy | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a quantitative systems pharmacology | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Spaink, Herman P |e verfasserin |4 aut | |
| 700 | 1 | |a Ottenhoff, Tom H M |e verfasserin |4 aut | |
| 700 | 1 | |a van der Graaf, Piet H |e verfasserin |4 aut | |
| 700 | 1 | |a van Hasselt, J G Coen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in pharmacological sciences |d 1989 |g 43(2022), 4 vom: 15. Apr., Seite 293-304 |w (DE-627)NLM012599670 |x 1873-3735 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2022 |g number:4 |g day:15 |g month:04 |g pages:293-304 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tips.2021.11.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2022 |e 4 |b 15 |c 04 |h 293-304 | ||